- Annovis Bio received FDA clearance to move forward with Phase 3 trials for buntanetap following an End-of-Phase 2 meeting on October 10, 2024.
- The pivotal trials will investigate buntanetap’s short-term symptomatic effects and potential long-term disease-modifying benefits in early-stage Alzheimer’s disease (“AD”) patients.
- Annovis Bio is targeting potential NDA submission within one year of the study’s initiation for symptomatic treatment, based on the results of a well-executed 6-month trial.
- The FDA raised no safety concerns regarding buntanetap and supported the use of its new crystal form in development.
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company focused on developing transformative therapies for neurodegenerative disorders, including Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), recently announced a significant milestone in its drug development process. On October 10, 2024, the company held an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (“FDA”), where it received clearance to proceed with pivotal Phase 3 studies for its lead compound, buntanetap.
Phase 3 Clinical Trials Overview:
- A 6-month study to confirm buntanetap’s symptomatic effects in early-stage AD patients.
- An 18-month study aimed at evaluating its long-term potential as a disease-modifying treatment.
The first, 6-month study is slated to begin in Q1 2025. Notably, if the initial 6-month study yields positive results, it may support an NDA submission of buntanetap as a symptomatic treatment within a year of…
NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
